DADC
ATRS

D.A. Davidson & Co’s Antares Pharma, Inc. ATRS Stock Holding History

D.A. Davidson & Co’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,000
Closed -$4K – 1807
2013
Q2 		$4K Buy
+1,000
New +$3.86K ﹤0.01% 1566

Other funds holding ATRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WHI
William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

D.A. Davidson & Co's ATRS Position: Q3 2013 in Review

D.A. Davidson & Co sold out of Antares Pharma, Inc. (ATRS) in Q3 2013, closing a stake of 1,000 shares — an estimated $4K sold.

D.A. Davidson & Co first reported a position in ATRS in Q2 2013 and held it in 1 quarter. The position peaked at $4K in Q2 2013. 97 funds tracked by Wall St. Rank hold ATRS as of Q3 2013.

  • D.A. Davidson & Co reported no remaining Antares Pharma, Inc. position as of Q3 2013 after selling out during the quarter.
  • D.A. Davidson & Co sold 1,000 Antares Pharma, Inc. shares in Q3 2013, an estimated $4K.
  • D.A. Davidson & Co first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 1 quarter.
  • D.A. Davidson & Co's Antares Pharma, Inc. position peaked at $4K in Q2 2013.
  • 97 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2013.

Based on D.A. Davidson & Co's 13F filing for Q3 2013, filed 14 Nov 2013.